Publications by authors named "Julia Lopez De-La-Cruz"
Article Synopsis
- - The study examined the impact of the HLADQA1*05 gene on patients with inflammatory bowel disease receiving first-line anti-TNF therapies (adalimumab or infliximab) from 2000 to 2021, focusing on response rates, loss of response (LOR), and adverse events (AE).
- - Out of 408 patients, HLADQA1*05 was linked to a significant increase in the risk of LOR and immunogenicity, especially related to infliximab, while HLADQA1*03 appeared to protect against LOR when using adalimumab.
- - The findings suggest that genetic factors like HLADQA1*05 and sex play crucial roles in treatment
Article Synopsis
- A 75-year-old woman came to the hospital with upper gastrointestinal bleeding and changes in her liver function tests.
- An MRI showed that she had a choledochoduodenal fistula, which was later confirmed by a gastroscopy.
- After surgery to fix the fistula, she was diagnosed with adenocarcinoma at the biliopancreatic junction, highlighting the rare way biliopancreatic tumors can present and the important role of endoscopy in diagnosis.
We present the case of a 57-year-old woman with metastatic colorectal cancer being treated with Bevacizumab and FOLFOX, who came to the emergency department with haematemesis. Gastroscopy showed a duodenal ulcer without active bleeding. Subsequently, he suffered haemodynamic instability and an Angio-CT scan revealed an aortoenteric fistula, requiring urgent surgery.
View Article and Find Full Text PDFBackground And Aims: Controversial data have been reported regarding the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Inflammatory Bowel Disease (IBD) population and IBD-related risk factors. The aim of the study was to assess the prevalence and risk factors associated with NAFLD and liver fibrosis in IBD participants compared with non-IBD controls.
Methods: Cross-sectional, case-control study including 741 IBD cases and 170 non-IBD controls, matched by sex and age.
The aim of the systematic review is to assess the prevalence and risk factors of liver fibrosis in patients with Inflammatory Bowel Disease (IBD) and Non-Alcoholic Fatty Liver Disease (NAFLD) and to discuss the role of liver fibrosis in the progression to hepatocellular carcinoma (HCC). We performed a structured search in PubMed, Web of Science, Embase, and Scopus up to 3 March 2023 to identify observational studies reporting liver fibrosis in patients with NAFLD and IBD. Quality of studies was assessed using the Newcastle-Ottawa Scale (NOS) score.
View Article and Find Full Text PDFChronic inflammation in patients with Inflammatory Bowel Disease (IBD) leads to an increased risk of colorectal cancer, small bowel cancer, intestinal lymphoma and cholangiocarcinoma. However, treatments for IBD have also been associated with an increased risk of neoplasms. Patients receiving Thiopurines (TPs) have an increased risk of hematologic malignancies, non-melanoma skin cancer, urinary tract neoplasms and cervical cancer.
View Article and Find Full Text PDFWe present the case of a 64-year-old man who, after a first episode of acute pancreatitis, was readmitted 20 days later due to severe epigastric pain and later an episode of upper gastrointestinal bleeding in the form of hematemesis and melena with hemodynamic instability. An urgent gastroscopy was performed at that time, revealing a probable gastrointestinal fistula in the duodenal bulb with an adherent clot without active bleeding at that time, so an urgent CT angiography was performed that revealed a necrotic peripancreatic collection with the presence of active bleeding inside from the pancreatoduodenal artery. Urgent arteriography identified an image compatible with arterial pseudoaneurysm dependent on the pancreaticoduodenal artery branch, which was successfully embolized.
View Article and Find Full Text PDF